# Addus HomeCare Corporation (ADUS) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ADUS/thesis · /stocks/ADUS/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: ADUS
step: 04
title: Financial Quality & Adversarial Sweep
generated: 2026-05-27
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Addus HomeCare Corporation (ADUS)

#### 1. Financial Statement Quality Assessment

##### Revenue Recognition
- **Method:** Services delivered basis — revenue recognized when personal care hours are delivered, hospice days are served, or home health visits are completed [S1]
- **Quality:** HIGH. No complex arrangements, no percentage-of-completion, no deferred revenue structures. Service delivery is the single trigger.
- **EVV verification:** Electronic Visit Verification provides a real-time audit trail of care delivery, reducing billing disputes and fraud risk
- **Adjustments needed:** NONE significant. Revenue as reported is reliable.

##### Cost of Revenue
- Predominantly caregiver wages + benefits + workers' compensation insurance
- Payroll timing: Weekly/bi-weekly; no significant timing distortions
- Workers' comp: Self-insured to varying degrees by state; actuarial reserves reflect expected claims
- **Quality:** HIGH. Direct labor cost is straightforward to verify against payroll records.

##### Goodwill ($997M = 70% of total assets as of FY2025)
- Largest balance sheet item; reflects 20+ acquisitions over 10+ years
- Annual impairment testing required (ASC 350); no goodwill impairment charges recorded in FY2021-FY2025 [S1]
- **Risk:** If acquired businesses underperform (e.g., Gentiva integration fails), impairment charges could be material (~$100-300M non-cash write-down possible in adverse scenario)
- **Assessment:** Management has consistently delivered accretive acquisitions; goodwill level is elevated but supported by stable cash flows

##### Intangible Assets ($102M)
- Primarily customer relationships, non-compete agreements, and trade names acquired via M&A
- Amortized over useful lives (7-20 years typically for customer relationships)
- Annual amortization ~$15-17M; reduces GAAP earnings but not economic earnings
- **Adjusted EBITDA addback:** Amortization is legitimately added back to understand economic earnings

##### Deferred Revenue / Working Capital
- No significant deferred revenue
- Working capital: Accounts receivable ~$200-250M (Medicaid/Medicare — typically 45-90 day payment cycles)
- DSO (Days Sales Outstanding): ~60-75 days (typical for government payor); government is slower but reliable
- **Quality:** MEDIUM. Medicaid AR can be complex; some state-specific payment delays occur. No evidence of channel stuffing or premature revenue recognition.

##### Earnings Quality Score: **B+ (High Quality)**
- Core operations generate genuine cash flows: OCF/Net Income ratio ~1.15-1.2x (above 1.0 = good quality)
- SBC (~$18-20M/year) reduces cash compensation but is a real economic cost; GAAP earnings appropriately reflect this
- No significant one-time items manipulating reported results (integration costs disclosed separately as "non-cash" but cash is still deployed)

#### 2. Adjusted Earnings vs. GAAP Reconciliation (FY2025)

| Metric | GAAP | Adjustment | Adjusted |
|--------|------|-----------|---------|
| Net Income | $96M | — | $96M |
| Add: Amortization | — | +$16M | — |
| Add: SBC | — | +$18M | — |
| Add: D&A (ex-amortization) | — | +$5M | — |
| Less: Tax on addbacks | — | (~$9M) | — |
| **Adjusted EBITDA** | — | — | **~$155M** |
| **Adjusted EPS (est.)** | **$5.22** | +$1.30 adj. | **~$6.40-6.50** |

*Note: Management uses "Adjusted EPS" excluding amortization of acquired intangibles; Q1 2026 reported $1.62 adjusted EPS vs. $1.36 GAAP [S2]*

#### 3. Adversarial Research Sweep

**Methodology:** Searched for short-seller reports, regulatory investigations, class action lawsuits, whistleblower filings, and bearish institutional research. Transcript analysis not performed (coverage-next-full path).

##### Finding 1: No Active Short-Seller Reports
- No published short-seller thesis found (Hindenburg, Muddy Waters, Citron, etc.)
- Short interest: Modest; MarketBeat shows routine short interest without spike indicators [S3]
- Assessment: **Clean** — no organized short-side campaign targeting ADUS

##### Finding 2: New York CDPAP Divestiture (Regulatory Adverse Event)
- **What happened:** New York's Consumer Directed Personal Assistance Program (CDPAP) underwent restructuring in 2024-2025; state created a new fiscal intermediary (FI) model; ADUS determined its NY operations were no longer financially viable
- **Impact:** Divested NY personal care operations; revenue loss not disclosed but material enough to trigger divestiture; ADUS cited "changes and uncertainty in New York regarding the CDPAP" [S1]
- **Assessment:** RESOLVED — NY operations exited; no ongoing NY regulatory risk. Demonstrates that state regulatory changes CAN force business model exits. Bears cite this as evidence that reimbursement risk is real and not theoretical.

##### Finding 3: Medicaid Billing Compliance Risk
- Home health and hospice companies are perennial OIG targets for false claims and billing fraud
- ADUS 10-K discloses routine legal proceedings; no material OIG investigation or settlement found [S1]
- EVV mandate compliance reduces personal care billing abuse risk
- **Assessment:** LOW RISK — No material compliance issue identified; EVV reduces fraud exposure vs. pre-EVV era

##### Finding 4: OBBBA Medicaid Eligibility Restrictions
- "One Big Beautiful Bill Act" (Trump-era federal legislation) includes provisions limiting Medicaid eligibility (immigration status restrictions, work requirements)
- ADUS is exposed: If Medicaid rolls shrink, personal care census shrinks proportionally
- **Assessment:** ACTIVE RISK — Not a fraud concern but a legitimate business risk. Effect size uncertain; Congressional outcomes subject to change.

##### Finding 5: Insider Selling Pattern
- Multiple insiders sold shares over 2024-2025 via 10b5-1 plans [S4]
- No open-market buying documented in the same period
- **Assessment:** MILD YELLOW FLAG — Selling is routine (tax-driven) but absence of open-market buying reduces conviction signal from insiders. CEO's 1.6% stake ($16M at current price) is material but not dominant.

##### Finding 6: Goodwill Concentration / Acquisition Risk
- $997M goodwill on $1.43B revenue and $1.08B equity — balance sheet is goodwill-heavy
- Gentiva acquisition ($340M, closed 2024) is the largest single acquisition; integration still in progress [S1]
- **Assessment:** ONGOING RISK — Not a quality/fraud issue, but an execution risk. If Gentiva underperforms, non-cash impairment charges possible.

##### Finding 7: Labor Wage Pressure
- Caregiver wages are the dominant cost (67% of revenue); minimum wage increases in IL, TX, and other states create structural cost pressure
- **Assessment:** INDUSTRY-WIDE RISK — Not ADUS-specific; peers face identical dynamic. ADUS's scale and EVV efficiency somewhat mitigate vs. smaller players.

#### 4. Financial Statement Flags Summary

| Issue | Severity | Status |
|-------|---------|--------|
| Revenue recognition | Low | Clean; service delivery basis |
| Goodwill impairment risk | Medium | Active; Gentiva integration key |
| NY CDPAP exit | Medium | Resolved; demonstrates state risk |
| Medicaid billing compliance | Low | No active investigation |
| Insider selling | Low | Routine 10b5-1; not conviction-driven |
| OBBBA Medicaid cuts | Medium-High | Active; legislative uncertainty |
| Short-seller activity | None | No organized short campaign |

**Overall Financial Quality Rating: B+ / Low Concern**
Core business generates real cash flows; accounting is straightforward; principal risks are regulatory/political, not accounting-based.

#### 5. Quality Adjustments for Modeling
1. Use **Adjusted EBITDA** (~$155M FY2025) for valuation; add back amortization of acquired intangibles (~$16M)
2. Use **Adjusted EPS** for earnings power comparisons; adds back ~$0.90/share intangible amortization
3. Treat goodwill as a permanent asset for DCF purposes (no amortization under GAAP); test acquisition economics separately
4. FCF is the cleanest profitability measure: $104M FY2025 / $111M OCF after $8M CapEx

#### Source Index
- [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
- [S2] Q1 2026 Earnings (8-K press release, May 2026) — via Stocktitan.net
- [S3] MarketBeat ADUS short interest — marketbeat.com/stocks/NASDAQ/ADUS/short-interest/
- [S4] SimplyWallSt — insider selling flag

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ADUS/fundamental

## Navigation

- Overview: /stocks/ADUS
- Financials (this page): /stocks/ADUS/financials
- Thesis: /stocks/ADUS/thesis
- Investment Memo: /stocks/ADUS/memo
- Coverage universe: /stocks